DescriptorNCT05364723
Place of Glycation in Diabetic Retinopathy
An observational study of Descriptor, run by Mohammed VI University Hospital.
Trial summary
1. Definition: Diabetic retinopathy is a microangiopathic complication of diabetes diabetes mellitus. Its pathophysiology includes glycation and intracellular hypoxia. Diabetic retinopathy (DR) is a microvascular complication of diabetes. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Descriptor
- How many people
- 1,000 participants
- Where
- No sites listed yet
- Study dates
- 15 May 2022to 15 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: diabetic population in the eastern region of Morocco
Who may be able to join
- Diabetic patients type 1 and type 2, of both sexes, and of all ages. Regular follow-up
Who cannot join
- Other types of diabetes. Irregular follow-up.
About this study
- Definition: Diabetic retinopathy is a microangiopathic complication of diabetes diabetes mellitus. Its pathophysiology includes glycation and intracellular hypoxia. Diabetic retinopathy (DR) is a microvascular complication of diabetes. It is the leading cause of It is the leading cause of blindness and visual impairment in people under the age of 60 in industrialized countries. Chronic hyperglycemia during diabetes plays a major role in the occurrence of diabetic diabetic retinopathy by promoting protein glycation and the accumulation of glycation end products (GTPs). GTPs are a heterogeneous group of compounds resulting from non-enzymatic and irreversible reactions between reducing sugars and amine groups of biological molecules such as proteins, lipids or nucleic acids.
- Interest: The aim of our work is to describe the mechanisms by which glycation participates in the pathophysiology of diabetic retinopathy and to discuss the use of AGEs as biomarkers in this biomarkers in this pathological context and the therapeutic means that limit the toxicity of of AGEs.
The study is designed through a retrospective and prospective observational study to establish the of glycation in the occurrence of diabetic retinopathy. It will describe the demographic demographic profiles, glycemic control, clinical and paraclinical status of patients with diabetic diabetic retinopathy and will evaluate the relationship between glycation and diabetic retinopathy as well as the factors that influence this glycation in these patients, and induce the occurrence and / or of diabetic retinopathy. The data collected will allow to improve the knowledge, the diagnosis and the treatment of diabetic diabetic retinopathy, as well as a good management of the patients who should benefit from a more individualized and individualized and adequate treatment.
- Conditions
- Descriptor
- Keywords
- glycation, diabetic retinopathy
- Medical subject headings
- Diabetic Retinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Other
no intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
distribution of diabetic retinopathy in eastern morocco
Measured: 1year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2022
- Study start15 May 2022 (estimated)
- Primary completion15 May 2025 (estimated)
- Study completion15 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DescriptorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mohammed VI University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Oujidi Wissale, Mohammed VI University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05364723
- Sponsor's protocol ID
- MohammedVIUHophtalmology
- Status last verified
- May 2022
- First submitted
- 3 May 2022
- Last updated
- 6 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Place of Glycation in Diabetic Retinopathy
- ClinicalTrials.gov ID
- NCT05364723
- Acronym / sponsor ID
- MohammedVIUHophtalmology
- Conditions
- Descriptor
- Keywords
- glycation, diabetic retinopathy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Mohammed VI University HospitalUniversity, hospital or other
- Study start
- 15 May 2022 (estimated)
- Primary completion
- 15 May 2025 (estimated)
- Study completion
- 15 May 2025 (estimated)
- First posted
- 6 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Definition: Diabetic retinopathy is a microangiopathic complication of diabetes diabetes mellitus. Its pathophysiology includes glycation and intracellular hypoxia. Diabetic retinopathy (DR) is a microvascular complication of diabetes. It is the leading cause of It is the leading cause of blindness and visual impairment in people under the age of 60 in industrialized countries. Chronic hyperglycemia during diabetes plays a major role in the occurrence of diabetic diabetic retinopathy by promoting protein glycation and the accumulation of glycation end products (GTPs). GTPs are a heterogeneous group of compounds resulting from non-enzymatic and irreversible reactions between reducing sugars and amine groups of biological molecules such as proteins, lipids or nucleic acids.
- Interest: The aim of our work is to describe the mechanisms by which glycation participates in the pathophysiology of diabetic retinopathy and to discuss the use of AGEs as biomarkers in this biomarkers in this pathological context and the therapeutic means that limit the toxicity of of AGEs.
The study is designed through a retrospective and prospective observational study to establish the of glycation in the occurrence of diabetic retinopathy. It will describe the demographic demographic profiles, glycemic control, clinical and paraclinical status of patients with diabetic diabetic retinopathy and will evaluate the relationship between glycation and diabetic retinopathy as well as the factors that influence this glycation in these patients, and induce the occurrence and / or of diabetic retinopathy. The data collected will allow to improve the knowledge, the diagnosis and the treatment of diabetic diabetic retinopathy, as well as a good management of the patients who should benefit from a more individualized and individualized and adequate treatment.
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- diabetic population in the eastern region of Morocco
Key inclusion criteria (1 listed)
- Diabetic patients type 1 and type 2, of both sexes, and of all ages. Regular follow-up
Key exclusion criteria (1 listed)
- Other types of diabetes. Irregular follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no intervention | Other | – |
Primary outcome
distribution of diabetic retinopathy in eastern morocco
Time frame: 1year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2022.
- Individual participant dataSharing planned: No
Related trials for Descriptor
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
RecruitingObservational study
Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function
Inflammation Biomarkers, Heart Failure
Not yet recruitingObservational study
Description of Clinicians' Predictive Abilities Before and After a Diffusion Tensor Imaging (DTI)
Diffusion Tensor Imaging Prognosis, Brain Injury, Traumatic
Not yet recruiting
MALMOS Technique for Selected Subaxial Cervical Spine Fractures
Cervical Spine Fractures
RecruitingObservational study
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Descriptor, run by Mohammed VI University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 May 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
distribution of diabetic retinopathy in eastern morocco (time frame: 1year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2022.